[go: up one dir, main page]

RU2005122444A - COMPOSITIONS IN THE FORM OF THYOTROPY-CONTAINING SOLUTIONS WITH HYDROFLUOROCHLORIDE - Google Patents

COMPOSITIONS IN THE FORM OF THYOTROPY-CONTAINING SOLUTIONS WITH HYDROFLUOROCHLORIDE Download PDF

Info

Publication number
RU2005122444A
RU2005122444A RU2005122444/15A RU2005122444A RU2005122444A RU 2005122444 A RU2005122444 A RU 2005122444A RU 2005122444/15 A RU2005122444/15 A RU 2005122444/15A RU 2005122444 A RU2005122444 A RU 2005122444A RU 2005122444 A RU2005122444 A RU 2005122444A
Authority
RU
Russia
Prior art keywords
acid
composition according
hfc
tiotropium
solvent
Prior art date
Application number
RU2005122444/15A
Other languages
Russian (ru)
Inventor
Забине ЗИКС (DE)
Забине ЗИКС
Кристель ШМЕЛЬЦЕР (DE)
Кристель Шмельцер
Фридрих ШМИДТ (DE)
Фридрих Шмидт
Original Assignee
Берингер Ингельхайм Фарма Гмбх Унд Ко.Кг (De)
Берингер Ингельхайм Фарма Гмбх Унд Ко.Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Берингер Ингельхайм Фарма Гмбх Унд Ко.Кг (De), Берингер Ингельхайм Фарма Гмбх Унд Ко.Кг filed Critical Берингер Ингельхайм Фарма Гмбх Унд Ко.Кг (De)
Publication of RU2005122444A publication Critical patent/RU2005122444A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (11)

1. Композиция в виде раствора для аэрозольного распыления, содержащая соль тиотропия, гидрофторуглерод (HFC) в качестве пропеллента, сорастворитель и неорганическую или органическую кислоту, отличающаяся тем, что концентрация кислоты лежит в интервале, который соответствует интервалу значений рН от 2,5 до 4,5 в водном растворе.1. The composition in the form of a solution for aerosol spraying, containing a salt of tiotropium, hydrofluorocarbon (HFC) as a propellant, a co-solvent and inorganic or organic acid, characterized in that the acid concentration lies in the range that corresponds to a pH range from 2.5 to 4 5 in aqueous solution. 2. Композиция по п.1, отличающаяся тем, что она содержит тиотропий в количестве от 0,00008 до 0,4%.2. The composition according to claim 1, characterized in that it contains tiotropium in an amount of from 0.00008 to 0.4%. 3. Композиция по п.1 или 2, отличающаяся тем, что противоион (анион), образующий вместе с тиотропием его соль, может представлять собой хлорид, бромид, иодид, метансульфонат или пара-толуолсульфонат.3. The composition according to claim 1 or 2, characterized in that the counterion (anion) that forms its salt together with tiotropium can be chloride, bromide, iodide, methanesulfonate or para-toluenesulfonate. 4. Композиция по п.1 или 2, отличающаяся тем, что гидрофторуглеродный пропеллент выбран из HFC-134(a), HFC-227, HFC-32, HFC-143(a), HFC-134, HFC-152a и их смесей.4. The composition according to claim 1 or 2, characterized in that the hydrofluorocarbon propellant is selected from HFC-134 (a), HFC-227, HFC-32, HFC-143 (a), HFC-134, HFC-152a and mixtures thereof . 5. Композиция по п.1 или 2, отличающаяся тем, что кислота выбрана из группы неорганических кислот, включающей соляную кислоту, серную кислоту, азотную кислоту и фосфорную кислоту.5. The composition according to claim 1 or 2, characterized in that the acid is selected from the group of inorganic acids, including hydrochloric acid, sulfuric acid, nitric acid and phosphoric acid. 6. Композиция по п.1 или 2, отличающаяся тем, что кислота выбрана из группы органических кислот, включающей аскорбиновую кислоту, лимонную кислоту, молочную кислоту, яблочную кислоту, бензойную кислоту и винную кислоту.6. The composition according to claim 1 or 2, characterized in that the acid is selected from the group of organic acids, including ascorbic acid, citric acid, lactic acid, malic acid, benzoic acid and tartaric acid. 7. Композиция по п.1 или 2, отличающаяся тем, что она содержит воду в количестве до примерно 5%.7. The composition according to claim 1 or 2, characterized in that it contains water in an amount up to about 5%. 8. Композиция по п.1 или 2, отличающаяся тем, что она содержит в качестве сорастворителя спирты, гликоли, простые эфиры гликоля, блоксополимеры этиленоксида и пропиленоксида, глицерин, полиоксиэтиленовые спирты, эфиры полиоксиэтилена и жирных кислот или гликофуролы.8. The composition according to claim 1 or 2, characterized in that it contains alcohols, glycols, glycol ethers, block copolymers of ethylene oxide and propylene oxide, glycerin, polyoxyethylene alcohols, polyoxyethylene fatty acid esters or glycofurols as co-solvent. 9. Композиция по п.1 или 2, отличающаяся тем, что сорастворитель присутствует в количестве от 5 до 50 мас.%.9. The composition according to claim 1 or 2, characterized in that the co-solvent is present in an amount of from 5 to 50 wt.%. 10. Композиция по п.1 или 2, отличающаяся тем, что она не содержит воду.10. The composition according to claim 1 or 2, characterized in that it does not contain water. 11. Применение композиции в виде раствора для аэрозольного распыления по одному из пп.1-10 для получения лекарственного средства, предназначенного для лечения заболеваний дыхательных путей.11. The use of the composition in the form of a solution for aerosol spraying according to one of claims 1 to 10 for the manufacture of a medicinal product intended for the treatment of diseases of the respiratory tract.
RU2005122444/15A 2002-12-16 2003-12-04 COMPOSITIONS IN THE FORM OF THYOTROPY-CONTAINING SOLUTIONS WITH HYDROFLUOROCHLORIDE RU2005122444A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02028238 2002-12-16
EP02028238.0 2002-12-16

Publications (1)

Publication Number Publication Date
RU2005122444A true RU2005122444A (en) 2007-01-27

Family

ID=32524008

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005122444/15A RU2005122444A (en) 2002-12-16 2003-12-04 COMPOSITIONS IN THE FORM OF THYOTROPY-CONTAINING SOLUTIONS WITH HYDROFLUOROCHLORIDE

Country Status (13)

Country Link
EP (1) EP1575588A1 (en)
JP (1) JP2006510680A (en)
KR (1) KR20050085650A (en)
CN (1) CN1726038A (en)
AU (1) AU2003303029A1 (en)
BR (1) BR0317340A (en)
CA (1) CA2510043A1 (en)
IL (1) IL169178A0 (en)
MX (1) MXPA05006383A (en)
PL (1) PL375868A1 (en)
RU (1) RU2005122444A (en)
WO (1) WO2004054580A1 (en)
ZA (1) ZA200503546B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273603B2 (en) * 2003-07-11 2007-09-25 Boehringer Ingelheim International Gmbh HFC solution formulations containing an anticholinergic
NZ563596A (en) * 2005-05-02 2011-01-28 Boehringer Ingelheim Int Crystalline form of tiotropium bromide anhydrate
EP1879888A2 (en) * 2005-05-02 2008-01-23 Boehringer Ingelheim International GmbH Crystalline forms of tiotropium bromide
US9108962B2 (en) 2005-12-19 2015-08-18 Sicor, Inc. Forms of tiotropium bromide and processes for preparation thereof
MX2007009988A (en) * 2005-12-19 2008-02-22 Sicor Inc Novel forms of tiotropium bromide and processes for preparation thereof.
EP2201934A1 (en) 2008-12-23 2010-06-30 CHIESI FARMACEUTICI S.p.A. Tiotropium aerosol formulation products with improved chemical stability
PE20121467A1 (en) 2009-12-23 2012-11-07 Chiesi Farma Spa AEROSOL FORMULATION FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
PE20121396A1 (en) 2009-12-23 2012-10-24 Chiesi Farma Spa PHARMACEUTICAL COMPOSITION INCLUDING GLYCOPYRONIUM BROMIDE AND FORMOTEROL
GB201200504D0 (en) * 2011-12-19 2012-02-22 Teva Branded Pharmaceutical Prod R & D Inc An inhaler
GB201200525D0 (en) * 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
JP6335798B2 (en) 2012-02-28 2018-05-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング New propellant-containing tiotropium formulation
CN104918604A (en) * 2012-10-23 2015-09-16 西普拉有限公司 Pharmaceutical composition
CA2930173A1 (en) * 2013-11-22 2015-05-28 Teva Branded Pharmaceutical Products R&D, Inc. An inhalable medicament
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
WO2018051132A1 (en) * 2016-09-19 2018-03-22 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
WO2018051128A1 (en) 2016-09-19 2018-03-22 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
WO2018051133A1 (en) 2016-09-19 2018-03-22 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
UA123919C2 (en) 2016-09-19 2021-06-23 Мехікем Флуор С.А. Де С.В. Pharmaceutical composition
GEP20217240B (en) * 2016-09-19 2021-03-25 Mexichem Fluor Sa De Cv Pharmaceutical composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG52459A1 (en) * 1992-12-09 1998-09-28 Boehringer Ingelheim Pharma Stabilized medicinal aerosol solution formulations
DE10056104A1 (en) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Drug compositions useful for treatment of respiratory diseases, especially asthma and chronic obstructive pulmonary disease comprises tiotropium salts and salmeterol salts

Also Published As

Publication number Publication date
CA2510043A1 (en) 2004-07-01
AU2003303029A1 (en) 2004-07-09
MXPA05006383A (en) 2005-08-29
ZA200503546B (en) 2006-10-25
KR20050085650A (en) 2005-08-29
BR0317340A (en) 2005-11-08
CN1726038A (en) 2006-01-25
PL375868A1 (en) 2005-12-12
IL169178A0 (en) 2007-07-04
WO2004054580A1 (en) 2004-07-01
JP2006510680A (en) 2006-03-30
EP1575588A1 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
RU2005122444A (en) COMPOSITIONS IN THE FORM OF THYOTROPY-CONTAINING SOLUTIONS WITH HYDROFLUOROCHLORIDE
CA2531847A1 (en) Hfc solution formulations containing an anticholinergic
AU2010246847B2 (en) Compositions suitable for the topical treatment of fungal infections of the skin and nails
CA2492976A1 (en) Solution for ungual and peri-ungual application
JPWO2000038731A1 (en) Topical medications
WO2005030211A8 (en) Aerosol formulation for inhalation, containing an anticholinergic agent
JP2017078088A5 (en)
JP2016514121A5 (en)
RU2005122729A (en) COMPOSITIONS FOR PREVENTION AND TREATMENT OF SYMPTOMS SIMILAR TO THE SYMPTOMS OF COLD AND INFLUENZA CONTAINING SELECTED MUCHABLE POLYMERS AND METHODS OF TREATMENT
HRP970622A2 (en) Aminhydrofluoride
JPWO2021029350A1 (en) Pharmaceutical composition containing an antifungal drug as an active ingredient
US20100292333A1 (en) Compositions suitable for the topical treatment of fungal infections of the skin and nails
JPWO2021205149A5 (en)
CN1794983B (en) Aqueous solution of oxylamidine and its preparation method and disinfectant
JP2001247446A (en) Cleaning agent with deep sea water
JP2005068076A (en) External liquid preparation containing tranexamic acids and cleaning agent
JP5435836B2 (en) Antifungal composition for external use
JP2005289959A (en) Oranexidine aqueous solution, its preparation method and disinfectant
JP2016539959A5 (en)
CA2666063C (en) Compositions suitable for the topical treatment of fungal infections of the skin and nails
CN107646862A (en) Aqueous olanexidine solution based on ascorbic acid and its preparation method and application
US20140205639A1 (en) Compositions suitable for the topical treatment of fungal infections of the skin and nails
HK1086200B (en) Aqueous olanexidine solution, method of preparing the same, and disinfectant
JPH03109321A (en) Drug composition for external use
HK1176817B (en) Aqueous olanexidine solution, method of preparing the same, and disinfectant

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20080220